Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLG95A
|
|||
| Drug Name |
NYX-2925
|
|||
| Synonyms |
2012536-16-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z] | Phase 2 | [1] | |
| Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7; ICD-9: 729.1] | Phase 2 | [2] | ||
| Company |
Aptinyx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H23N3O4
|
|||
| Canonical SMILES |
CC(C)C(=O)N1CCCC12CN(C2=O)C(C(C)O)C(=O)N
|
|||
| InChI |
1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m0/s1
|
|||
| InChIKey |
NFXPEHLDVKVVKA-RBZYPMLTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04146896) Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04147858) Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia. U.S. National Institutes of Health. | |||
| REF 3 | NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther. 2018 Sep;366(3):485-497. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.